ZNTL

Zentalis Pharmaceuticals, Inc.

12.04 USD
-0.03 (-0.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Zentalis Pharmaceuticals, Inc. stock is down -7.1% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 May’s closed higher than April. 100% of analysts rate it a buy.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

  • HC Wainwright & Co.
    Wed May 8, 15:21
    buy
    confirm
  • Stifel
    Wed May 8, 09:33
    buy
    confirm